BACKGROUND: The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied. METHODS: We performed an analysis involving HIV/HBV-coinfected patients in 13 cohorts who initiated cART. The end-point was LRD--that is, death with concomitant decompensated liver disease (DLD) or hepatocellular carcinoma--as the main cause. Incidence rates of LRD after initiation of cART were expressed as number of events per 100 person-years of follow-up (PYFU). A Poisson regression model adjusted for cohort, gender, mode of HIV transmission, CD4+ T-cell count at cART initiation, liver disease pre-cART, duration of 3TC before cART, and hepatitis C virus was used to assess the association between use of 3TC and risk of LRD. Results: We analysed 2,041 patients. Follow-up after starting cART was 7,648 PYFU (5,569 spent on 3TC-containing regimens) with a median per person of 48 months (range: 2-91). Of the total, 217 subjects died; 57 deaths were liver-related resulting in a rate of 7.5 per 1,000 PYFU [95% confidence intervals (CI): 5.6-9.7]. The relative risk of LRD per extra year of 3TC use was 0.73 (95% CI: 0.59-0.90, P = 0.004). CONCLUSION: The use of 3TC was associated with a reduced risk of LRD over 4 years of follow-up. This study supports the current view that the use of 3TC as part of cART should be considered in patients who are tested positive for HBsAg.

Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis / Puoti, M; Cozzi Lepri, A; Paraninfo, G; Arici, C; Moller, Nf; Lundgren, Jd; Ledergerber, B; Rickenbach, M; Suarez Lozano, I; Garrido, M; Dabis, F; Winnock, M; Milazzo, L; Gervais, A; Raffi, F; Gill, J; Rockstroh, J; Ourishi, N; Mussini, Cristina; Castagna, A; De Luca, A; Monforte, A; HBV HIV International Intercohort Study, Group. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - STAMPA. - 11:(2006), pp. 567-574.

Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.

MUSSINI, Cristina;
2006

Abstract

BACKGROUND: The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied. METHODS: We performed an analysis involving HIV/HBV-coinfected patients in 13 cohorts who initiated cART. The end-point was LRD--that is, death with concomitant decompensated liver disease (DLD) or hepatocellular carcinoma--as the main cause. Incidence rates of LRD after initiation of cART were expressed as number of events per 100 person-years of follow-up (PYFU). A Poisson regression model adjusted for cohort, gender, mode of HIV transmission, CD4+ T-cell count at cART initiation, liver disease pre-cART, duration of 3TC before cART, and hepatitis C virus was used to assess the association between use of 3TC and risk of LRD. Results: We analysed 2,041 patients. Follow-up after starting cART was 7,648 PYFU (5,569 spent on 3TC-containing regimens) with a median per person of 48 months (range: 2-91). Of the total, 217 subjects died; 57 deaths were liver-related resulting in a rate of 7.5 per 1,000 PYFU [95% confidence intervals (CI): 5.6-9.7]. The relative risk of LRD per extra year of 3TC use was 0.73 (95% CI: 0.59-0.90, P = 0.004). CONCLUSION: The use of 3TC was associated with a reduced risk of LRD over 4 years of follow-up. This study supports the current view that the use of 3TC as part of cART should be considered in patients who are tested positive for HBsAg.
2006
11
567
574
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis / Puoti, M; Cozzi Lepri, A; Paraninfo, G; Arici, C; Moller, Nf; Lundgren, Jd; Ledergerber, B; Rickenbach, M; Suarez Lozano, I; Garrido, M; Dabis, F; Winnock, M; Milazzo, L; Gervais, A; Raffi, F; Gill, J; Rockstroh, J; Ourishi, N; Mussini, Cristina; Castagna, A; De Luca, A; Monforte, A; HBV HIV International Intercohort Study, Group. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - STAMPA. - 11:(2006), pp. 567-574.
Puoti, M; Cozzi Lepri, A; Paraninfo, G; Arici, C; Moller, Nf; Lundgren, Jd; Ledergerber, B; Rickenbach, M; Suarez Lozano, I; Garrido, M; Dabis, F; Winnock, M; Milazzo, L; Gervais, A; Raffi, F; Gill, J; Rockstroh, J; Ourishi, N; Mussini, Cristina; Castagna, A; De Luca, A; Monforte, A; HBV HIV International Intercohort Study, Group
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/860146
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 33
social impact